Use app for best experience!
Available for Android Device.

Mankind Pharma Limited IPO Detail

Mankind Pharma Limited IPO Detail

Incorporated in 1991, Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations across various acute and chronic therapeutic areas and several consumer healthcare products.

In India, the business is active in a number of acute and chronic therapeutic fields, including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins/minerals/nutrients, and respiratory.

It has over 36 brands, including Manforce (Rx), Moxikind-CV, Amlokind-AT, Unwanted-Kit, Candiforce, Gudcef, Glimestar-M, Prega News, Dydroboon, Codistar, Nurokind-Gold, Nurokind Plus-RF, Nurokind-LC, Asthakind-DX, Cefakind, Monticope, Telmikind-H, Telmikind, Gudcef-CV, and Unwanted-72, among them.

Mankind Pharma has one of the largest distribution networks of medical representatives in the Indian pharmaceutical market ("IPM"). Over 80% of doctors in India prescribed their formulations and has been ranked number 4th in terms of domestic sales during the Financial Year 2022.

The company has been awarded The Best of Bharat Awards 2022 by exchange4media in the year 2022, Silver Medal from National Awards for Manufacturing Competitiveness Assessment 2021 instituted by International Research Institute for Manufacturing, and Silver Award for Good Health Brand at IHW Awards 2021 in the year 2021, Best Condom Brand of the Year award at Sex Brand Awards Pharma OTC Company of the Year Award at Pharma Excellence Awards 2018, Award for Best Design in Healthcare at Healthcare Leadership Awards 2017, and Amity HR Excellence Award for Performance Management at the 8th Global HR Summit 2011.

Company Promoters

Ramesh Juneja, Rajeev Juneja, Sheetal Arora, Ramesh Juneja Family Trust, Rajeev Juneja Family Trust and Prem Sheetal Family Trust

IPO Details

IPO Opening DateApr 25, 2023
IPO Closing DateApr 27, 2023
Issue TypeBook Built Issue IPO
Face Value₹1 per equity share
IPO Price ₹1026 - 1080 per equity share
Market Lot13 Shares
Min Order Quantity13 Shares
Listing AtBSE, NSE
Issue Size₹4,326.36 Cr
Fresh Issue-
Offer for Sale₹4,326.36 Cr
Retail Portion 35%

IPO Subscription (Bidding Detail)

Day 1 0.08x 0.33x 0.11x - 0.15x
Day 2 1.86x 1.02x 0.25x - 0.88x
Day 3 49.16x 3.80x 0.92x - 15.32x

IPO Tentative Timetable

The Mankind Pharma Limited IPO open date is Apr 25, 2023, and the close date is Apr 27, 2023. The issue may list on May 09, 2023.

IPO Open DateApr 25, 2023
IPO Close DateApr 27, 2023
Basis of Allotment DateMay 03, 2023
Initiation of RefundsMay 04, 2023
Credit of Shares to Demat AccountMay 05, 2023
IPO Listing DateMay 09, 2023

IPO Lot Size

The Mankind Pharma Limited IPO market lot size is 13 shares. A retail-individual investor can apply for up to 14 lots (182 shares or ₹196560).

ApplicationLotsSharesAmount (Cut-off)

IPO Promoter Holding

Pre Issue Share Holding79.00%
Post Issue Share Holding

Company Financials:

For the year/period ended (₹ in Cr.)

Financial Year Total Assets Total Revenue Profit After Tax
31-Mar-20 5,073.29 5,975.65 1,056.15
31-Mar-21 6,372.63 6,385.38 1,293.03
31-Mar-22 9,147.74 7,977.58 1,452.96
31-Dec-22 9,273.75 6,777.82 1,015.98

Objects of the Issue:

All of the offer proceeds will be received by the selling shareholders in proportion to the offered shares that each selling shareholder sold as part of the offer; the company will not receive any of the offer proceeds.

Mankind Pharma Limited IPO Registrar:

KFin Technologies Limited

Mankind Pharma Limited IPO Lead Manager(s):

Kotak Mahindra Capital Company Limited Axis Capital Limited IIFL Securities Ltd Jefferies India Private Limited J.P. Morgan India Private Limited

Company Contact Information:

Mankind Pharma Limited

208, Okhla Industrial Estate


New Delhi 110020